Bayer settles Serenade-related litigation with Bion Tech Inc.
Bayer CropScience and Bion Tech, Taiwan, Republic of China, a producer of biological crop protection agents, have settled a patent infringement case in Korea. Under the settlement, Bayer CropScience granted Bion Tech a royalty-bearing license to sell lipopeptide-containing products based on Bion Tech’s proprietary Bacillus subtilis Y1336 strain. Bion Tech´s strain Y1336 produces agrastatin, which is covered by claims related to lipopeptides in Bayer CropScience’s patent portfolio. These lipopeptides contribute to the unique properties of Bayer’s Serenade™ products. The license extends to various countries, with a focus on Asia. Financial terms of the settlement were not disclosed.
Mike Miille, Head of Business Management Biologics at Bayer CropScience, commented: "Biologicals play a significant role in shaping farming´s future because they help to increase yield and optimize grower´s flexibility." Bayer CropScience remains committed to investing in research and development to offer farmers worldwide integrated crop protection solutions combining seeds, chemical and biological crop protection products, as well as services and product stewardship measures. "Strong patent protection is the basis for this innovation," Miille added.
- International Year of Soils set for 2015
- Extra care needed for wintertime fuel handling
- CLA issues statement on EPA’s neonicotinoid report
- Cattle futures bucked the bearish ag market trend Thursday
- Valent launches new low VOC plant growth regulator
- Thursday's export data had mixed crop market implications
- ValueAct buys stake in fertilizer dealer Agrium
- DuPont Crop Protection to sell certain assets to Bayer
- Critics of Dow herbicide sue U.S. EPA over approval
- Six tips to help professionals take leaps of faith
- Nitrogen fertilization rates for corn production
- Landmark Services Co-op, Curry Seeds sign agreement